Elections › Corporate Influence › PFIZER INC.

🏛️ PFIZER INC.

CORPORATE LOBBYING & ELECTION INFLUENCE PROFILE

$34.7M
Lobbying Spend
$0
Campaign Spending
54
Lobbyists
0
Races Influenced
69
LDA Filings
Lobbying Issue Areas
🏥 Healthcare & Pharma🏭 Trade & Manufacturing🛡️ Defense & Security💰 Finance & Banking
Filing Quarters
first_quarterfourth_quartersecond_quarterthird_quarter
Specific Lobbying Issues
Medical Supply Chain Resiliency Act; Promotion of robust IP protection for biopharma innovations before WTO and in current and future FTAs
Implementation of the drug pricing provisions in the Inflation Reduction Act Drug pricing and prescription digital therapeutics
Issues related to budget reconciliation, including H.Con.Res. 14 and S.Con.Res. 7.
Issues related to prescription drug value, including H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; and implemen
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act.
Where the Money Is Going
Race Campaign $ Candidate(s)
No race-level spending data linked yet.
Source: Senate LDA lobbying disclosures + FEC campaign finance data + USAspending.gov via Hammerhead Intelligence
Lobbying $ = annual reported federal lobbying expenditures (company-wide). Campaign $ = IE spending directed at candidates in specific races. Govt Contracts $ = federal awards from USAspending.gov.
Last updated: 2026-04-25